Uso de ruxolitinib como tratamiento puente al trasplante alogénico de progenitores hematopoyéticos en un paciente con mielofibrosis idiopática

Barba, Pere; Fox, María Laura; Blanco, Adoración; Valcárcel, David.
Med. clín (Ed. impr.) ; 144(4): 184-185, feb. 2015.
Artículo en Español | IBECS (España) | ID: ibc-132159

Documentos relacionados

  1. Management of myelofibrosis after ruxolitinib failure.
  2. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
  3. JAK inhibitors for asthma.
  4. [The place of JAK2 inhibitors in the treatment of myelofibrosis. An amendment to the recommendations for diagnosis and treatment of Ph negative myeloproliferations of the Czech group for Ph- myeloproliferative disorders (CZEMP)].
  5. Pathogenetic insights from the treatment of rheumatoid arthritis.
  6. Translating JAKs to Jakinibs.
  7. JAK Inhibition in STAT1 Gain-of-Function-Mediated Treatment-Resistant Autoimmune Hepatitis.
  8. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
  9. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
  10. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.